Levofloxacin

Drug Profile

Levofloxacin

Alternative Names: Cravit Intravenous; Cravit Oral; DR-3355; Levaquin; Levaquin Oral Solution; Tavanic

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antibacterials; Fluoroquinolones; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute exacerbations of chronic bronchitis; Acute sinusitis; Anthrax; Bacterial infections; Community-acquired pneumonia; Nosocomial pneumonia; Pneumonia; Prostatitis; Pyelonephritis; Respiratory tract infections; Sinusitis; Skin and soft tissue infections; Urinary tract infections
  • Registered Gynaecological infections; Postoperative infections; Tuberculosis

Most Recent Events

  • 26 Jul 2016 The US FDA approved label for levofloxacin carries a boxed warning
  • 15 Mar 2016 Biomarkers information updated
  • 24 Sep 2015 Registered for Urinary tract infections, Postoperative infections and gynaecological infections in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top